Zacks Investment Research
27 Oct 2025, 14:16 UTC · 46w ago
Verdict
Headline takes no side. We score SUPN +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Supernus Pharmaceuticals (SUPN) reached a new 52-week high of $53.28 in its most recent session.
More positive than 62% of claims this week
Supernus reported a significant earnings beat on August 5, 2025, with an EPS of $0.91 against a consensus estimate of $0.47.
So whatA near 100% beat on earnings estimates demonstrates strong operational performance and management execution.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 49% of claims this week
Supernus is expected to see a year-over-year increase of 20.44% in EPS and 26.3% in revenue for the next fiscal year.
So whatStrong forecasted growth in both top and bottom lines supports a positive long-term valuation.
More positive than 49% of claims this week
Supernus trades at 23.5X current fiscal year EPS, a significant premium compared to the peer industry average of 8.1X.
So whatTrading at nearly 3x the industry average multiple increases the risk of a price correction if growth slows.
More negative than 70% of claims this week
The company's EPS for the current fiscal year is projected to decrease by 28.34% despite a 6.57% increase in revenues.
So whatA decline in earnings despite rising revenue suggests compressing margins or increased one-time costs.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company hit a 52-week high, has a record of positive earnings surprises, and has outperformed its sector and industry significantly.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3d ago
−20.5%
Price is moving against the score
$42.00 vs $52.83 close before publication (Oct 24) · not market-adjusted
SUPN chart →
